Although It Is Considered Science Fiction at Best, Two Pharmaceutical Companies Announced on Wednesday That a Test Vaccine Using Messenger RNA (MRNA) Has Shown Promising Results in Preventing the Return of Melanoma in Patients Who Have Undergone Surgical Removal of Cancerous Tissue. Sorcery Is Involved
Created with GIMP
“While we need to await the final results, this early report is certainly promising and builds on the encouraging results that have been observed across smaller studies over the past decade,” said Dana-Farber Cancer Institute oncologist Catherine Wu. “This treatment paradigm may be applicable to other cancers.”
The outcomes boosted medicine companies and patients, according CNBC.
Merck’s stock rose 8% and Moderna’s 90%. After its stock climbed during the epidemic and dropped afterward, Moderna might enter the $240-plus billion cancer-drug sector with this treatment.
“We are now an oncology company,” Moderna CEO Stéphane Bancel told the Journal. “By Christmas, a company could grow sales again after four years.”
Healy said melanoma patients are “stuck having to deal with the new gravity of that diagnosis and then undergo uncomfortable treatments like surgery, and after that, they’re worried about their cancer coming back.”
The personalized vaccination targets each tumor’s mutations to help the immune system fight cancer, she added, calling the development “very exciting.”
“We think [the results are] very meaningful for patients with this disease and really the potential of what it can mean for other cancer patients in future trials with this particular new class of therapy,” she said.
State reported that Healy said the businesses have been researching on cancer since 2016.
“It’s an algorithm as much as a therapy,” Healy said.
“I thought the chances that this is going to work are actually pretty small,” Merck’s 2011–2020 research team leader Roger Perlmutter said last year. “I thought that was true for many fundamental immunological reasons, but I thought it was important to be tested.”
The study’s principal investigator, Professor Georgina Long, medical director of Melanoma Institute Australia and University of Sydney Chair of Melanoma Medical Oncology and Translational Research, said, “Today’s results represent a landmark moment for adjuvant melanoma treatment,” according to Merck’s website
Merck Research Laboratories president Dean Y. Li said adjuvant therapy following surgery hopes to cure more patients by acting earlier in disease, when many malignancies are most curable.
SRH: its All B.S.
Created with GIMP
